Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burnier

Showing results (261-270 of 284) with videos related to

Pageof 29
Sort By:
Kidney International|October 10, 1998
Circadian variations of renal sodium handling in patients with orthostatic hypotensionA Pechère-Bertschi, J Nussberger, J Biollaz, et al.
Journal of Human Hypertension|April 13, 2012
Inflammatory markers and blood pressure: sex differences and the effect of fat mass in the CoLaus StudyM Pruijm, P Vollenweider, V Mooser, et al.
Clinical Pharmacology and Therapeutics|August 1, 1991
Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteersM Burnier, M Ganslmayer, F Perret, et al.
Hypertension (Dallas, Tex. : 1979)|November 22, 1997
Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humansR Weber, A Pechère-Bertschi, D Hayoz, et al.
Rheumatology (Oxford, England)|October 18, 2000
Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenonD Hayoz, G Bizzini, B Noël, et al.
International Journal of Clinical Practice|October 17, 2012
Management of hypertension in patients with diabetes mellitus and metabolic syndrome in Swiss primary careH H Schäfer, J D de Villiers, I Sudano, et al.
Clinical Nephrology|May 29, 2009
Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysisJ Trachsler, Z Glück, M Dickenmann, et al.
Journal of Cardiovascular Pharmacology|May 1, 1989
Bolus injections of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndromeM Burnier, V Mooser, J P Wauters, et al.
Clinical Pharmacology and Therapeutics|November 7, 2008
Vascular effects of RWJ-676070, a selective combined V1a/V2 vasopressin receptor antagonistL Coltamai, M Bucher, M P Maillard, et al.
American Journal of Ophthalmology|December 15, 1990
Identification of Toxoplasma gondii in paraffin-embedded sections by the polymerase chain reactionA P Brézin, C E Egwuagu, M Burnier, et al.
Pageof 29

Showing results (261-270 of 284) with videos related to

Sort By:
Pageof 29
Kidney International|October 10, 1998
Circadian variations of renal sodium handling in patients with orthostatic hypotensionA Pechère-Bertschi, J Nussberger, J Biollaz, et al.
Journal of Human Hypertension|April 13, 2012
Inflammatory markers and blood pressure: sex differences and the effect of fat mass in the CoLaus StudyM Pruijm, P Vollenweider, V Mooser, et al.
Clinical Pharmacology and Therapeutics|August 1, 1991
Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteersM Burnier, M Ganslmayer, F Perret, et al.
Hypertension (Dallas, Tex. : 1979)|November 22, 1997
Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humansR Weber, A Pechère-Bertschi, D Hayoz, et al.
Rheumatology (Oxford, England)|October 18, 2000
Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenonD Hayoz, G Bizzini, B Noël, et al.
International Journal of Clinical Practice|October 17, 2012
Management of hypertension in patients with diabetes mellitus and metabolic syndrome in Swiss primary careH H Schäfer, J D de Villiers, I Sudano, et al.
Clinical Nephrology|May 29, 2009
Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysisJ Trachsler, Z Glück, M Dickenmann, et al.
Journal of Cardiovascular Pharmacology|May 1, 1989
Bolus injections of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndromeM Burnier, V Mooser, J P Wauters, et al.
Clinical Pharmacology and Therapeutics|November 7, 2008
Vascular effects of RWJ-676070, a selective combined V1a/V2 vasopressin receptor antagonistL Coltamai, M Bucher, M P Maillard, et al.
American Journal of Ophthalmology|December 15, 1990
Identification of Toxoplasma gondii in paraffin-embedded sections by the polymerase chain reactionA P Brézin, C E Egwuagu, M Burnier, et al.
Pageof 29